Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Bell Michael BrianOwnership Type:Direct OwnershipSecurities:RESTRICTED STOCK UNITSNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,931Price:--
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Bell Michael BrianOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,703Price:$26.78
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Bell Michael BrianOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:4,931Price:--
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Potter Myrtle SOwnership Type:Direct OwnershipSecurities:RESTRICTED STOCK UNITSNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-68Price:--
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Potter Myrtle SOwnership Type:Direct OwnershipSecurities:RESTRICTED STOCK UNITSNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:68Price:--
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Eltoukhy HelmyOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:8,600Price:$26.15
-
Mar 14, 2023 (filed on Mar 16, 2023)Insider Name:Eltoukhy HelmyOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:84,452Price:$26.33
-
Mar 14, 2023 (filed on Mar 15, 2023)Insider Name:Talasaz AmirAliOwnership Type:Indirect OwnershipSecurities:COMMON STOCKNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:4,250Price:$26.40
-
Mar 14, 2023 (filed on Mar 15, 2023)Insider Name:Talasaz AmirAliOwnership Type:Indirect OwnershipSecurities:COMMON STOCKNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:4,250Price:$26.40
-
Mar 14, 2023 (filed on Mar 15, 2023)Insider Name:Talasaz AmirAliOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:8,500Price:$26.40
Filings by filing date
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Bell Michael BrianOwnership Type:Direct OwnershipSecurities:RESTRICTED STOCK UNITSNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,931Price:--
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Bell Michael BrianOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,703Price:$26.78
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Bell Michael BrianOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:4,931Price:--
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Potter Myrtle SOwnership Type:Direct OwnershipSecurities:RESTRICTED STOCK UNITSNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-68Price:--
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Potter Myrtle SOwnership Type:Direct OwnershipSecurities:RESTRICTED STOCK UNITSNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:68Price:--
-
Mar 15, 2023 (filed on Mar 16, 2023)Insider Name:Eltoukhy HelmyOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:8,600Price:$26.15
-
Mar 14, 2023 (filed on Mar 16, 2023)Insider Name:Eltoukhy HelmyOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:84,452Price:$26.33
-
Mar 14, 2023 (filed on Mar 15, 2023)Insider Name:Talasaz AmirAliOwnership Type:Indirect OwnershipSecurities:COMMON STOCKNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:4,250Price:$26.40
-
Mar 14, 2023 (filed on Mar 15, 2023)Insider Name:Talasaz AmirAliOwnership Type:Indirect OwnershipSecurities:COMMON STOCKNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:4,250Price:$26.40
-
Mar 14, 2023 (filed on Mar 15, 2023)Insider Name:Talasaz AmirAliOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:8,500Price:$26.40
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3100 Hanover Street PALO ALTO CA 94304 |
Tel: | 1-657-2545417 |
Website: | https://guardanthealth.com |
IR: | See website |
Key People | ||
Helmy A. Eltoukhy Chairman of the Board, Co-Chief Executive Officer | Amirali Talasaz President, Co-Chief Executive Officer, Director | Michael Bell Chief Financial Officer |
John Gomes Saia Senior Vice President, General Counsel, Corporate Secretary | Craig Eagle Chief Medical Officer | Christopher Freeman Chief Commercial Officer |
Business Overview |
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also has developed Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. The Company's GuardantINFORM platform is used to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers. |
Financial Overview |
For the fiscal year ended 31 December 2022, Guardant Health Inc revenues increased 20% to $449.5M. Net loss increased 61% to $654.6M. Revenues reflect United States segment increase of 19% to $420.6M, International segment increase of 37% to $28.9M. Higher net loss reflects Research and development expense increase of 42% to $347.2M (expense), Sales and marketing expense increase of 56% to $274.4M (expense). |
Employees: | 1,793 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2,485M as of Dec 31, 2022 |
Annual revenue (TTM): | $449.54M as of Dec 31, 2022 |
EBITDA (TTM): | -$508.39M as of Dec 31, 2022 |
Net annual income (TTM): | -$654.59M as of Dec 31, 2022 |
Free cash flow (TTM): | -$386.92M as of Dec 31, 2022 |
Net Debt Last Fiscal Year: | $126.16M as of Dec 31, 2022 |
Shares outstanding: | 102,663,734 as of Feb 17, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |